Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics (NASDAQ: HOTH) has announced a partnership with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. The collaboration includes an immunohistochemistry study conducted with Charles River Laboratories Montreal ULC, marking a significant step in HT-KIT's preclinical development.
The study focuses on developing and optimizing staining methods for c-Kit markers, which are important targets in HT-KIT's therapeutic mechanism. It includes processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine marker presence, along with comprehensive reporting to support HT-KIT's development.
HT-KIT is a preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers, representing a potential advancement in precision oncology therapies.
Hoth Therapeutics (NASDAQ: HOTH) ha annunciato una collaborazione con OnTargetx R&D Inc. per avanzare la ricerca del suo terapeutico anti-cancro, HT-KIT. La collaborazione include uno studio di immunoistochimica condotto con Charles River Laboratories Montreal ULC, segnando un passo significativo nello sviluppo preclinico di HT-KIT.
Lo studio si concentra sullo sviluppo e l'ottimizzazione dei metodi di colorazione per i marcatori c-Kit, che sono obiettivi importanti nel meccanismo terapeutico di HT-KIT. Include l'elaborazione e la valutazione qualitativa dei campioni di tessuto da parte di un patologo certificato per determinare la presenza dei marcatori, insieme a report dettagliati per supportare lo sviluppo di HT-KIT.
HT-KIT è un candidato terapeutico preclinico che mira a c-Kit, un recettore tirosina chinasi coinvolto in vari tipi di tumori, rappresentando un potenziale progresso nelle terapie di oncologia di precisione.
Hoth Therapeutics (NASDAQ: HOTH) ha anunciado una asociación con OnTargetx R&D Inc. para avanzar en la investigación de su terapia contra el cáncer, HT-KIT. La colaboración incluye un estudio de inmunohistoquímica realizado con Charles River Laboratories Montreal ULC, marcando un paso significativo en el desarrollo preclínico de HT-KIT.
El estudio se centra en desarrollar y optimizar los métodos de tinción para los marcadores c-Kit, que son objetivos importantes en el mecanismo terapéutico de HT-KIT. Incluye el procesamiento y la evaluación cualitativa de muestras de tejido por un patólogo certificado para determinar la presencia de marcadores, junto con informes completos para apoyar el desarrollo de HT-KIT.
HT-KIT es un candidato terapéutico preclínico que se dirige a c-Kit, una quinasa de tirosina receptora involucrada en varios tipos de cáncer, representando un avance potencial en las terapias de oncología de precisión.
Hoth Therapeutics (NASDAQ: HOTH)는 암 치료제인 HT-KIT의 연구를 발전시키기 위해 OnTargetx R&D Inc.와 파트너십을 발표했습니다. 이 협력은 Charles River Laboratories Montreal ULC에서 수행된 면역조직화학 연구를 포함하며, HT-KIT의 전임상 개발에 있어 중요한 진전을 의미합니다.
이 연구는 HT-KIT의 치료 메커니즘에서 중요한 타겟인 c-Kit 마커에 대한 염색 방법의 개발 및 최적화에 초점을 맞추고 있습니다. 여기에는 마커의 존재를 확인하기 위해 인증된 병리학자가 조직 샘플을 처리하고 질적 평가를 수행하며, HT-KIT의 개발을 지원하기 위한 종합 보고서도 포함됩니다.
HT-KIT는 여러 암에 관련된 수용체 타이로신 키나제인 c-Kit를 목표로 하는 전임상 치료 후보로, 정밀 종양학 치료의 잠재적인 발전을 나타냅니다.
Hoth Therapeutics (NASDAQ: HOTH) a annoncé un partenariat avec OnTargetx R&D Inc. pour faire avancer la recherche sur son thérapeutique anticancéreux, HT-KIT. Cette collaboration comprend une étude en immunohistochimie réalisée avec Charles River Laboratories Montreal ULC, marquant un pas significatif dans le développement préclinique de HT-KIT.
L'étude se concentre sur le développement et l'optimisation des méthodes de coloration pour les marqueurs c-Kit, qui sont des cibles importantes dans le mécanisme thérapeutique de HT-KIT. Elle inclut le traitement et l'évaluation qualitative d'échantillons de tissu par un pathologiste certifié pour déterminer la présence des marqueurs, ainsi que des rapports complets pour soutenir le développement de HT-KIT.
HT-KIT est un candidat thérapeutique préclinique ciblant c-Kit, une kinases de tyrosine réceptrice impliquée dans divers cancers, représentant un potentiel avancement dans les thérapies d'oncologie de précision.
Hoth Therapeutics (NASDAQ: HOTH) hat eine Partnerschaft mit OnTargetx R&D Inc. angekündigt, um die Forschung für sein krebskämpfendes Therapeutikum HT-KIT voranzutreiben. Die Zusammenarbeit umfasst eine immunhistochemische Studie, die mit Charles River Laboratories Montreal ULC durchgeführt wird und einen bedeutenden Schritt in der präklinischen Entwicklung von HT-KIT darstellt.
Die Studie konzentriert sich auf die Entwicklung und Optimierung von Färbemethoden für c-Kit-Marker, die wichtige Ziele im therapeutischen Mechanismus von HT-KIT sind. Diese umfasst die Verarbeitung und qualitative Bewertung von Gewebeproben durch einen zertifizierten Pathologen, um die Marker-Präsenz zu bestimmen, sowie umfassende Berichterstattung zur Unterstützung der Entwicklung von HT-KIT.
HT-KIT ist ein präklinischer therapeutischer Kandidat, der auf c-Kit abzielt, einen rezeptorassoziierten Tyrosinkinase, die an verschiedenen Krebsarten beteiligt ist, und stellt einen potenziellen Fortschritt in der präzisionsonkologischen Therapie dar.
- Strategic partnership established with OnTargetx R&D for HT-KIT development
- Collaboration with Charles River Laboratories for immunohistochemistry study
- HT-KIT still in preclinical phase, indicating long path to potential commercialization
Insights
The collaboration between Hoth Therapeutics and OnTargetx R&D marks a important advancement in the development of HT-KIT, their cancer-fighting therapeutic. The focus on c-Kit markers through immunohistochemistry studies is particularly significant, as c-Kit receptor tyrosine kinase plays a pivotal role in multiple cancer pathways, including gastrointestinal stromal tumors (GIST), acute myeloid leukemia and certain types of melanoma.
The partnership with Charles River Laboratories, a respected contract research organization, adds substantial credibility to the preclinical development process. Immunohistochemistry studies are essential in drug development as they provide important visual evidence of how the therapeutic interacts with specific cellular targets, helping to validate the drug's mechanism of action and potentially predict its efficacy.
This development phase is particularly important for several reasons:
- The optimization of staining methods for c-Kit markers will provide valuable data about HT-KIT's targeting precision
- Evaluation by board-certified pathologists adds scientific rigor to the validation process
- The comprehensive reporting will be important for future regulatory submissions and potential partnership discussions
While this represents positive progress in HT-KIT's development, investors should note that preclinical studies are early-stage research and successful results would still require extensive clinical trials before potential commercialization. The targeted approach focusing on c-Kit puts Hoth in competition with established cancer therapeutics, but also positions them in a growing precision medicine market segment.
The study focuses on:
Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism.
Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.
Comprehensive reporting and insights to support the continued development of HT-KIT.
"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are committed to driving innovative solutions that can transform patient care."
The study aligns with Hoth Therapeutics' mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.
About HT-KIT
HT-KIT is Hoth's preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers. This candidate represents a potential advancement in precision oncology therapies.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-partners-with-ontargetx-rd-to-advance-research-for-cancer-fighting-ht-kit-cancer-therapeutic-302372193.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the purpose of Hoth Therapeutics' partnership with OnTargetx R&D for HT-KIT?
What is HT-KIT's current development stage as of February 2025?
What role does Charles River Laboratories play in HOTH's HT-KIT development?
What is the therapeutic target of HOTH's HT-KIT cancer treatment?
